PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma

Abstract Cholangiocarcinoma (CCA) is an aggressive malignancy with limited therapeutic options. Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib. Biomarker studies that can identify potential responders to mTK...

Полное описание

Библиографические подробности

Главные авторы:	Jia-ming Hu, Hui-qiang Liu, Ming-hui Zhang, Tian-li Chen, An-da Shi, Qiang Gao, Yun-jia Liu, Xin Wang, Kai-yang Sun, Jian Deng, Yun-fei Xu, Chang Pan, Kang-shuai Li, Zong-li Zhang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2025-11-01
Серии:	Journal of Experimental & Clinical Cancer Research
Предметы:	Cholangiocarcinoma Surufatinib IGF1R PTPN9 CAF
Online-ссылка:	https://doi.org/10.1186/s13046-025-03594-2
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!